CDC Identifies Four Urgent Superbug Threats Driving Rising Healthcare Costs in the U.S.
The CDC warns of four urgent drug-resistant superbugs causing over 50,000 annual deaths. Learn about the risks, transmission, and impact on U.S. healthcare.
POLICY WIRE — Atlanta, USA — A fresh report from the Centers for Disease Control and Prevention (CDC) highlights the escalating danger of drug-resistant pathogens across the United States. Federal health officials are currently tracking 25 total pathogens, with 19 identified as significant contributors to 9.7 million infections and 50,800 deaths annually.
The agency has classified four specific superbugs as urgent threats: Candida auris, Acinetobacter, Enterobacterales, and Neisseria gonorrhoeae. These pathogens are frequently encountered in clinical environments, where they account for more than 42,000 deaths and generate nearly $12 billion in annual healthcare expenditures.
Projections suggest the crisis will intensify in the coming decades. Researchers estimate that annual fatalities linked to superbugs in North America could reach 317,000 by the year 2050. CDC Director Dr. Erica Schwartz stated, Antimicrobial resistance threatens modern medicine and puts millions of Americans at risk every year.
Candida auris, a lethal fungus, has surged nearly tenfold since 2019, recording over 6,700 infections this year. Primarily affecting patients in hospitals and long-term care facilities, the fungus can persist on surfaces for weeks and lead to severe outcomes like organ failure, sepsis, and shock.
Carbapenem-resistant Acinetobacter, or CRAB, has seen a resurgence in infections, with 9,497 cases and 817 deaths reported in 2023. These infections, which cost the healthcare system over $355 million, disproportionately impact patients on ventilators or those recovering from surgical procedures.
Similarly, Carbapenem-resistant Enterobacterales (CRE) caused 14,878 hospital-based infections and 1,252 deaths in 2023, resulting in $174 million in costs. The CDC warns that the rapid spread of carbapenemase-producing CRE could lead to further increases in both infection rates and mortality.
The fourth urgent threat, gonorrhea, accounts for 787,000 cases annually in the U.S. and over $214 million in costs. Beyond the risk of infertility and HIV transmission, the infection can cause life-threatening ectopic pregnancies and complications for infants during childbirth.
Beyond these four, the CDC is monitoring 13 additional serious threats, including drug-resistant Shigella, C. diff, nontyphoidal Salmonella, and Staph. Recent outbreaks of Shigella and Salmonella have underscored the ongoing challenge of managing these resistant bacteria in the general population.
Reporting by Policy-Wire (PW)





